LCBiot-LVVVGACGVGK-OH

Ref. 3D-PP48773

Informations sur le produit

• Nom: LCBiot-LVVVGACGVGK-OH

Description

Peptide LCBiot-LVVVGACGVGK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using LCBiot-LVVVGACGVGK-OH include the following: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target Y Wang, B Zhong, C Xu, D Zhan , S Zhao, H Wu, M Liu - Iscience, 2023 - cell.comhttps://www.cell.com/iscience/pdf/S2589-0042(23)00157-8.pdf Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery V Kantae, R Polanski, HJ Lewis, A Haider - ACS Chemical , 2022 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acschembio.2c00483 Tuning cyclometalated gold (III) for cysteine arylation and ligand-directed bioconjugation S Gukathasan , S Parkin , EP Black - Inorganic , 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.inorgchem.1c01517 Quantifying KRAS G12C covalent drug inhibitor activity in mouse tumors using mass spectrometry JC Tran , T Hunsaker, C Bell, TP Ma, E Chan - Analytical , 2023 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.analchem.2c04417 Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured JA Kaczmarczyk , RR Roberts, BT Luke, KC Chan - Oncotarget, 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487723/ Comparative Microsomal Proteomics of A Model Lung Cancer Cell Line NCI-H23 Reveals Distinct Differences Between Molecular Profiles of 3D and 2D Cultured J Blonder , JA Kaczmarczyk , RR Roberts, BT Luke - 2020 - researchsquare.comhttps://www.researchsquare.com/article/rs-72194/latest SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors C Fedele , S Li, KW Teng , C Foster , D Peng, H Ran - bioRxiv, 2020 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2020.05.30.125138.abstract CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer A Prahallad, A Weiss, H Voshol, G Kerr , K Sprouffske - Cancer Research, 2023 - AACRhttps://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-23-1127/730017

• Marque: Biosynth